{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T13:59:29Z","timestamp":1781963969534,"version":"3.54.5"},"reference-count":27,"publisher":"BMJ","issue":"8","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"published-print":{"date-parts":[[2018,8]]},"abstract":"<jats:sec><jats:title>Background and purpose<\/jats:title><jats:p>To evaluate ruthenium-106 (Ru106) brachytherapy as eye-conserving treatment of iris melanomas (IMs) and iridociliary melanomas (ICMs).<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>Eighty-eight patients received Ru106 brachytherapy between 2006 and 2016. Primary outcome was local control, and secondary outcomes were metastasis, survival, eye preservation, complications and visual acuity (VA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall median follow-up was 36 months. Of 88 patients, 58 (65.9%) had IM and 30 (34.1%) had ICM. ICM were on average larger and more advanced than IM. Local failure-free survival at 3years was 98.9% (SE 1.2%). Metastasis-free survival was 98.2% (SE 1.8%) at 3years; no deaths due to melanoma occurred during follow-up. Eye preservation rate was 97.7%. Treatment-related toxicities were mostly mild and observed in 80.7% of the patients. Common toxicities were worsening of pre-existing or new cataract (51.1%), dry eyes (29.5%) and glaucoma (20.5%). VA was not affected by Ru106 brachytherapy, with only 2.3% having VA &lt;0.33 (low vision) at follow-up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Ru106 for IM and ICM yielded excellent local control (98.9%) and eye preservation (97.7%). Toxicities were common, but mostly mild and transient. Moreover, Ru106 did not affect visual acuity.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bjophthalmol-2017-310688","type":"journal-article","created":{"date-parts":[[2017,11,9]],"date-time":"2017-11-09T17:20:44Z","timestamp":1510248044000},"page":"1154-1159","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":13,"title":["Ruthenium-106 brachytherapy for iris and iridociliary melanomas"],"prefix":"10.1136","volume":"102","author":[{"given":"Marina","family":"Marinkovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanda","family":"Horeweg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam S","family":"Laman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaco C","family":"Bleeker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn","family":"Ketelaars","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Femke P","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gre P M","family":"Luyten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carien L","family":"Creutzberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,11,9]]},"reference":[{"key":"2020050713014870000_102.8.1154.1","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2008.150292"},{"key":"2020050713014870000_102.8.1154.2","unstructured":"Dutch_Cancer_Registry. Incidence of uveal melanoma in the Netherlands. 2016 http:\/\/wwwcijfersoverkankernl\/selecties\/dataset_1\/img580f4edbdb55d (Publication date 4 Feb 2016. Accessed 25 Oct 2016)."},{"key":"2020050713014870000_102.8.1154.3","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1097\/IAE.0b013e31824d09a8","article-title":"Clinical spectrum and prognosis of uveal melanoma based on age at presentation in 8,033 cases","volume":"32","author":"Shields","year":"2012","journal-title":"Retina"},{"key":"2020050713014870000_102.8.1154.4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.2010.01967.x"},{"key":"2020050713014870000_102.8.1154.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(01)01007-8"},{"key":"2020050713014870000_102.8.1154.6","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2009.208"},{"key":"2020050713014870000_102.8.1154.7","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1001\/archopht.117.2.170","article-title":"Plaque radiotherapy of uveal melanoma with predominant ciliary body involvement","volume":"117","author":"G\u00fcnd\u00fcz","year":"1999","journal-title":"Arch Ophthalmol"},{"key":"2020050713014870000_102.8.1154.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(02)02241-9"},{"key":"2020050713014870000_102.8.1154.9","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ophtha.2012.06.053","article-title":"Iris melanoma management with iodine-125 plaque radiotherapy in 144 patients: impact of melanoma-related glaucoma on outcomes","volume":"120","author":"Shields","year":"2013","journal-title":"Ophthalmology"},{"key":"2020050713014870000_102.8.1154.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.09.014"},{"key":"2020050713014870000_102.8.1154.11","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.clindermatol.2014.10.010","article-title":"Melanoma of the eye: revealing hidden secrets, one at a time","volume":"33","author":"Shields","year":"2015","journal-title":"Clin Dermatol"},{"key":"2020050713014870000_102.8.1154.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2005.01.050"},{"key":"2020050713014870000_102.8.1154.13","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.survophthal.2016.12.012","article-title":"Radiotherapeutic and surgical management of iris melanoma: a review","volume":"62","author":"Popovic","year":"2017","journal-title":"Surv Ophthalmol"},{"key":"2020050713014870000_102.8.1154.14","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/j.ophtha.2015.01.026","article-title":"American Joint Committee on Cancer Classification of Uveal Melanoma (Anatomic Stage) predicts prognosis in 7,731 patients: the 2013 Zimmerman Lecture","volume":"122","author":"Shields","year":"2015","journal-title":"Ophthalmology"},{"key":"2020050713014870000_102.8.1154.15","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(02)03751-3"},{"key":"2020050713014870000_102.8.1154.16","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.79.4.306"},{"key":"2020050713014870000_102.8.1154.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2009.08.007"},{"key":"2020050713014870000_102.8.1154.18","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1038\/eye.2011.222","article-title":"Plaque radiotherapy treatment with ruthenium-106 for iris malignant melanoma","volume":"25","author":"Tsimpida","year":"2011","journal-title":"Eye"},{"key":"2020050713014870000_102.8.1154.19","doi-asserted-by":"publisher","DOI":"10.3129\/i09-097"},{"key":"2020050713014870000_102.8.1154.20","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.ijrobp.2011.09.033","article-title":"Lack of radiation maculopathy after palladium-103 plaque radiotherapy for iris melanoma","volume":"83","author":"Yousef","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2020050713014870000_102.8.1154.21","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejca.2016.09.009","article-title":"Ruthenium-106 brachytherapy for choroidal melanoma without transpupillary thermotherapy: similar efficacy with improved visual outcome","volume":"68","author":"Marinkovic","year":"2016","journal-title":"Eur J Cancer"},{"key":"2020050713014870000_102.8.1154.22","doi-asserted-by":"publisher","DOI":"10.1148\/110.3.681"},{"key":"2020050713014870000_102.8.1154.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2010.03.023"},{"key":"2020050713014870000_102.8.1154.24","unstructured":"WHO. Visual impairment and blindness. http:\/\/wwwwhoint\/blindness\/Change_the_Definition_of_Blindnesspdf."},{"key":"2020050713014870000_102.8.1154.25","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(96)00075-X"},{"key":"2020050713014870000_102.8.1154.26","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.ophtha.2017.02.015","article-title":"Regression patterns of iris melanoma after palladium-103 ((103)Pd) plaque brachytherapy","volume":"124","author":"Chaugule","year":"2017","journal-title":"Ophthalmology"},{"key":"2020050713014870000_102.8.1154.27","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(98)91121-6"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjophthalmol-2017-310688","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T08:55:39Z","timestamp":1601110539000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjophthalmol-2017-310688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,9]]},"references-count":27,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,7,19]]},"published-print":{"date-parts":[[2018,8]]}},"alternative-id":["10.1136\/bjophthalmol-2017-310688"],"URL":"https:\/\/doi.org\/10.1136\/bjophthalmol-2017-310688","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,9]]}}}